Revolution Medicines Opens Daraxonrasib Access for Pancreatic Cancer After 13-Month Survival Result
Updated
Updated · WBUR News · Jul 8
Revolution Medicines Opens Daraxonrasib Access for Pancreatic Cancer After 13-Month Survival Result
3 articles · Updated · WBUR News · Jul 8
Summary
Revolution Medicines has begun a U.S. expanded access program for daraxonrasib, making the drug available before FDA approval to eligible metastatic pancreatic cancer patients who already received chemotherapy.
Resolute 302 showed median overall survival of about 13 months on daraxonrasib versus roughly 6 months on chemotherapy, a statistically significant gain in a cancer with more than 90% mortality.
The KRAS-targeting drug also improved quality of life and pain control; rash was the main side effect, becoming substantial enough for dose holds or reductions in about 10% to 15% of patients.
Because KRAS mutations appear in nearly 95% of pancreatic cancers, investigators say the result could reshape treatment beyond rare mutation-specific therapies and support trials in earlier-stage disease.
Now that a powerful treatment exists, can this same drug be used to stop pancreatic cancer before it even starts?
With a breakthrough pill available, are personalized cancer vaccines the next major frontier in fighting this disease?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: FDA Fast-Tracks Access Amid Unprecedented Hope and Challenges
Overview
Pancreatic cancer is one of the deadliest cancers, with over 50,000 Americans dying each year and a five-year survival rate of just 3% for those with advanced disease. Because there are few effective treatments and a great unmet medical need, the FDA acted quickly on daraxonrasib, an investigational drug, by granting it expedited designations and launching an Expanded Access Program. This swift response aims to give hope to patients who have limited options, showing how urgent the situation is and how new therapies like daraxonrasib could make a real difference for those facing this challenging cancer.